Dr. Jim Hu is a urologic oncologist with his undergraduate degree in Economics, his Master’s in Public Health in Health Policy and Management from Johns Hopkins University, and his Medical Degree from Baylor College of Medicine. He completed his Urology Residency at the David Geffen School of Medicine at UCLA and his Robotic Surgery/Urologic Oncology Fellowship in 2004 at City of Hope National Medical Center.
In 2015, it is estimated that 8400 U.S. men were diagnosed with testis cancer and 380 men died from testis cancer. Testis cancer is most commonly diagnosed in the second and third decade of life, with the average age of diagnosis being 33 years. For unknown reasons, testis cancer is becoming more prevalent in the U.S. and elsewhere.
Men are three to four times more likely than women to be diagnosed with bladder cancer. The most common type of bladder cancer is transitional cell carcinoma, comprising 90% of all bladder cancers. Transitional cell carcinomas are staged according to the depth of bladder wall invasion, which also has bearing on treatment options. Superficial transitional cell carcinomas are in the lining of the bladder and have not invaded the deeper bladder muscle wall, whereas muscle invasive cancers have penetrated this layer and are more likely to spread.
Dr. Schlegel is an internationally acclaimed expert in the treatment of male infertility, especially the interface of male factor treatment with assisted reproductive techniques. His work has also clarified the importance of hormonal therapy, sperm analysis and genetic studies in the evaluation of men with infertility. He was awarded the 1996 Established Clinician Award by The European Society for Human Reproduction and Embryology.
The Brady Urologic Health Center is located within an 8,000 square foot suite on the ninth floor of the Starr Pavilion at Weill Cornell Medicine/New York-Presbyterian Hospital and is composed of a close-knit team of physicians, working together to provide treatment for the broad spectrum of urologic conditions.
Of the 1.65 million Americans diagnosed with cancer in 2015, approximately 508,470 (31%) were classified as cancers of the genitourinary system. The most common non-skin cancer diagnosed annually in U.S. men is prostate cancer, with an incidence of 220,000, followed by cancers affecting both men and women, such as bladder cancer in 74,000 Americans and kidney cancer in 61,500 Americans. Less common cancers of the adrenal gland and male genitourinary system also comprise urologic oncology.